PHP
SNDX icon

Parkman Healthcare Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Parkman Healthcare Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1M Buy
901,511
+327,488
+57% +$7.12M 2.17% 15
2025
Q4 		$12.1M Sell
574,023
-272,876
-32% -$4.76M 1.15% 32
2025
Q3 		$13M Sell
846,899
-20,914
-2% -$274K 1.36% 25
2025
Q2 		$8.13M Buy
867,813
+272,826
+46% +$3M 0.93% 39
2025
Q1 		$7.31M Buy
594,987
+68,014
+13% +$959K 0.87% 41
2024
Q4 		$6.97M Buy
526,973
+18,690
+4% +$320K 0.93% 40
2024
Q3 		$9.78M Sell
508,283
-92,415
-15% -$1.91M 1.25% 28
2024
Q2 		$12.3M Sell
600,698
-184,113
-23% -$3.85M 1.65% 20
2024
Q1 		$18.7M Buy
784,811
+46,222
+6% +$1.03M 2.29% 10
2023
Q4 		$16M Buy
738,589
+526,141
+248% +$8.09M 2.25% 15
2023
Q3 		$3.08M Buy
212,448
+4,182
+2% +$79.1K 0.57% 50
2023
Q2 		$4.36M Buy
+208,266
New +$4.34M 0.76% 39
2021
Q1 		– Sell
-31,386
Closed -$698K – 95
2020
Q4 		$698K Buy
31,386
+1,381
+5% +$28.6K 0.18% 76
2020
Q3 		$443K Buy
30,005
+5
+0% +$76 0.12% 83
2020
Q2 		$445K Buy
+30,000
New +$457K 0.13% 76

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Parkman Healthcare Partners's SNDX Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Syndax Pharmaceuticals (SNDX) stake by 57% in Q1 2026, buying an estimated $7.12M and bringing the position to 901,511 shares worth $21.1M. The position accounts for 2.17% of the portfolio, ranked #15.

Parkman Healthcare Partners first reported a position in SNDX in Q2 2020 and has held it in 15 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Parkman Healthcare Partners held 901,511 shares of Syndax Pharmaceuticals worth $21.1M as of Q1 2026.
  • Parkman Healthcare Partners bought 327,488 Syndax Pharmaceuticals shares in Q1 2026, an estimated $7.12M.
  • Syndax Pharmaceuticals made up 2.17% of Parkman Healthcare Partners's portfolio in Q1 2026, its #15 holding.
  • Parkman Healthcare Partners first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.